Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Curr Med Chem. 2011 Sep 1;18(27):4169–4174. doi: 10.2174/092986711797189673

Table 1.

Aptamers that have entered clinical investigation in cardiovascular diseases.

Aptamer Target Company Development Stage
ARC1779 vWF Archemix Phase I, II
ARC1172 vWF Archemix Phase I
ARC183 Thrombin Archemix Phase I
NU172 Thrombin ARCA Biopharma, Inc. Phase I, II
REG1 (RB006/RB007) Factor IXa Regado Biosciences Phase I, IIa, IIb